top of page
Stem Cells Then, Now, and Later
The History, Progression, and Future of Stem Cell Research
Companies
Name: Caladrius Biosciences
Location: New York, New York
CEO: David J. Mazzo, PhD
Mission Statement: "At Caladrius Biosciences, our mission is to bring new, innovative and treatment paradigm-changing medical therapies to market based on our unique expertise and experience, and in so doing, to improve patients’ lives and create value for our shareholders."
Company Overview: Caladrius Biosciences focuses primarily on cell and tissue manipulation and assists with the collection, manipulation and storage of cells and human tissue. In other words, Caladrius is one of the world's leading cell therapy companies, using bothe stem and somatic cells to rebuild tissue. Although they are based in New York, the company plans to spread to other continents in the near future.
Business Type: Cellular Therapy
Year Founded: 2006
Name: Living Cell Technologies
Business Type: Regenerative Medicine
Location: Melbourne, VIC, Australia
Founders: Professor Bob Elliott and David Collinson
Mission Statement: "Living Cell Technologies was initially formed to commercialise research into treatments for type 1 diabetes. Today we are a recognised world leader in pioneering cell transplant therapeutics.
Year Founded: 1999
Company Overview: Living Cell Technologies' primary focus began as the treatment of type one diabetes and Parkinson's disease. Formerly known as Diatranz, the company formed a partnership with Otsuka Pharmaceutical Factory, Inc. to better fund their attempts at fighting diabetes and Parkinson's. Recently, the company has announced a second product line based on transplanting choroid plexus brain cells that has the potential to treat neurodegenerative diseases, such as Parkinson's disease.
Name: Mesoblast
Business Type: Regenerative Medicine
Location: Melbourne, VIC, Australia
Founder and CEO: Silviu Itescu
Year Founded: 2004
Mission Statement: "The Company has leveraged its proprietary technology platform, which is based on specialized cells known as mesenchymal lineage adult stem cells (MLCs), to establish a broad portfolio of late-stage product candidates.These allogeneic, ‘off-the-shelf’ cell product candidates target advanced stages of diseases with high, unmet medical needs including cardiovascular diseases, orthopedic disorders, oncology and hematology diseases, and immune-mediated and inflammatory conditions. We believe we are well positioned to have the first industrially manufactured allogeneic stem cell product approved in the United States."
Company Overview: Mesoblast was founded originally to provide treatments for inflammatory ailments, cardiovascular disease and back pain, but has evolved over the years to include the implementation of stem cell therapies and treatments. The company is primarily based in Japan but has extensive plns to provide other nations, including the United States with life-saving treatments.
Mission Statement: "Regeneus Ltd (ASX: RGS) is an Australian clinical-stage regenerative medicine company developing a patented portfolio of cell therapies to address significant unmet medical needs in the human and animal health markets with a focus on musculoskeletal disease, oncology and dermatology. Regeneus’ strategy is to continue to develop innovative technologies partnering with larger companies with commercialisation capabilities to develop and market the products."
Name: Regeneus
Business Type: Stem Cell Therapy
Location: Pymble, NSW, Australia
Founder and Former CEO: Professor Graham Vesey
Year Founded: 2007
Company Overview: Regeneus has three main platforms fro achieving their goal of addressing unadressed medical concerns:
-
"Human and animal adipose-derived mesenchymal stem cells (MSCs) for the treatment of musculoskeletal diseases"
-
"Human and animal immunotherapy personalised cancer vaccine for the treatment of a wide variety of cancers"
-
"Stem cell secretions (cell free supernatant) – CFS technology harnessing the therapeutic potential of mesenchymal stem cells for skincare treatments"
The approach the company is taking to integrate stem cell based procedures into medical treatments of common diseases is what sets them apart from any other stem cell therapeutic company.
Name: TiGenix Living Medicines
Business Type: Cell Therapy
Location: Leuven, Belgium
Founders: Dr. Frank P. Luyten and Gil Beyen
Year Founded: 2000
Mission Statement: "TiGenix is a leading European cell therapy company with an advanced clinical stage pipeline of adult stem cell programmes, and a commercialised product. The stem cell programmes are based on proprietary validated platforms of allogeneic expanded stem cells targeting autoimmune, inflammatory and heart diseases. Built on solid pre-clinical and CMC packages, they are being developed in close consultation with the European Medicines Agency."
Company Overview: TiGenix is a stem cell therapeutic company headquartered in Belgium with facilities in Spain. Their chief goal is to target autoimmune, inflammatory, and heart diseases by using allogeneic (genetically dissimilar) expanded stem cells to treat, cure, and prevent harmful diseases.
bottom of page